Suppr超能文献

直接口服抗凝剂的使用情况及处方模式。

Utilization and prescribing patterns of direct oral anticoagulants.

作者信息

Whitworth Maegan M, Haase Krystal K, Fike David S, Bharadwaj Ravindra M, Young Rodney B, MacLaughlin Eric J

机构信息

Department of Pharmacy Practice, Texas Tech University Health Sciences Center (TTUHSC) School of Pharmacy.

Department of Internal Medicine.

出版信息

Int J Gen Med. 2017 Mar 10;10:87-94. doi: 10.2147/IJGM.S129235. eCollection 2017.

Abstract

BACKGROUND

Scant literature exists evaluating utilization patterns for direct oral anticoagulants (DOACs).

OBJECTIVES

The primary objective was to assess DOAC prescribing in patients with venous thromboembolism (VTE) and nonvalvular atrial fibrillation (NVAF) in outpatient clinics. Secondary objectives were to compare utilization between family medicine (FM) and internal medicine (IM) clinics, characterize potentially inappropriate use, and identify factors associated with adverse events (AEs).

METHODS

This was a retrospective cohort study of adults with NVAF or VTE who received a DOAC at FM or IM clinics between 10/19/2010 and 10/23/2014. Descriptive statistics were utilized for the primary aim. Fisher's exact test was used to evaluate differences in prescribing using an adapted medication appropriateness index. Logistic regression evaluated factors associated with inappropriate use and AEs.

RESULTS

One-hundred twenty patients were evaluated. At least 1 inappropriate criterion was met in 72 patients (60.0%). The most frequent inappropriate criteria were dosage (33.0%), duration of therapy (18.4%), and correct administration (18.0%). Apixaban was dosed inappropriately most frequently. There was no difference in dosing appropriateness between FM and IM clinics. The odds of inappropriate choice were lower with apixaban compared to other DOACs (odds ratio [OR]=0.088; 95% confidence interval [CI] 0.008-0.964; =0.047). Twenty-seven patients (22.5%) experienced an AE while on a DOAC, and the odds of bleeding doubled with each inappropriate criterion met (OR=1.949; 95% CI 1.190-3.190; =0.008).

CONCLUSION

Potentially inappropriate prescribing of DOACs is frequent with the most common errors being dosing, administration, and duration of therapy. These results underscore the importance of prescriber education regarding the appropriate use and management of DOACs.

摘要

背景

评估直接口服抗凝剂(DOACs)使用模式的文献较少。

目的

主要目的是评估门诊静脉血栓栓塞症(VTE)和非瓣膜性心房颤动(NVAF)患者中DOAC的处方情况。次要目的是比较家庭医学(FM)诊所和内科(IM)诊所之间的使用情况,确定潜在的不适当使用情况,并识别与不良事件(AE)相关的因素。

方法

这是一项回顾性队列研究,研究对象为2010年10月19日至2014年10月23日期间在FM或IM诊所接受DOAC治疗的NVAF或VTE成人患者。描述性统计用于主要目的。采用Fisher精确检验,使用改编的药物合理性指数评估处方差异。逻辑回归评估与不适当使用和AE相关的因素。

结果

共评估了120例患者。72例患者(60.0%)至少符合1条不适当标准。最常见的不适当标准是剂量(33.0%)、治疗持续时间(18.4%)和正确给药(18.0%)。阿哌沙班的剂量不当最为常见。FM诊所和IM诊所在剂量合理性方面没有差异。与其他DOAC相比,阿哌沙班选择不当的几率较低(优势比[OR]=0.088;95%置信区间[CI]0.008-0.964;P=0.047)。27例患者(22.5%)在服用DOAC期间发生了AE,每符合1条不适当标准,出血几率就会增加一倍(OR=1.949;95%CI1.190-3.190;P=0.008)。

结论

DOAC的潜在不适当处方很常见,最常见的错误是剂量、给药和治疗持续时间。这些结果强调了对开处方者进行关于DOAC适当使用和管理教育的重要性。

相似文献

1
Utilization and prescribing patterns of direct oral anticoagulants.
Int J Gen Med. 2017 Mar 10;10:87-94. doi: 10.2147/IJGM.S129235. eCollection 2017.
3
Quality of clinical direct oral anticoagulant prescribing and identification of risk factors for inappropriate prescriptions.
Br J Clin Pharmacol. 2020 Aug;86(8):1567-1574. doi: 10.1111/bcp.14264. Epub 2020 Mar 13.
4
Appropriateness of Dabigatran and Rivaroxaban Prescribing in Qatar: A 5-Year Experience.
J Cardiovasc Pharmacol Ther. 2018 Mar;23(2):155-161. doi: 10.1177/1074248417731536. Epub 2017 Oct 4.
5
7
The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
J Stroke Cerebrovasc Dis. 2018 Nov;27(11):3280-3288. doi: 10.1016/j.jstrokecerebrovasdis.2018.07.028. Epub 2018 Aug 16.
9
Inappropriate dosing of direct oral anticoagulants: findings from a clinical vignette study and physician survey.
J Mark Access Health Policy. 2023 Oct 29;11(1):2267327. doi: 10.1080/20016689.2023.2267327. eCollection 2023.

引用本文的文献

2
Impact of a pharmacist intervention on DOAC knowledge and satisfaction in ambulatory patients.
J Thromb Thrombolysis. 2023 Feb;55(2):346-354. doi: 10.1007/s11239-022-02743-0. Epub 2022 Dec 12.
3
Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.
PLoS One. 2022 Apr 20;17(4):e0266658. doi: 10.1371/journal.pone.0266658. eCollection 2022.
4
Appropriateness of Prescribing Rivaroxaban at King Khalid University Hospital Riyadh.
Cureus. 2022 Jan 5;14(1):e20977. doi: 10.7759/cureus.20977. eCollection 2022 Jan.
5
Prescribing Errors With Direct Oral Anticoagulants and Their Impact on the Risk of Bleeding in Patients With Atrial Fibrillation.
J Cardiovasc Pharmacol Ther. 2021 Nov;26(6):601-610. doi: 10.1177/10742484211019657. Epub 2021 Jun 1.
7
Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD-VTE.
Res Pract Thromb Haemost. 2021 Feb 20;5(2):326-341. doi: 10.1002/rth2.12482. eCollection 2021 Feb.
8
Thromboembolism in Older Adults.
Front Med (Lausanne). 2021 Jan 27;7:470016. doi: 10.3389/fmed.2020.470016. eCollection 2020.
9
Anticoagulant Utilization and Cost Analysis among Cardiology Inpatients in a Tertiary Care Teaching Hospital of Western Nepal.
Adv Pharmacol Pharm Sci. 2020 Nov 23;2020:8890921. doi: 10.1155/2020/8890921. eCollection 2020.
10
Quality of clinical direct oral anticoagulant prescribing and identification of risk factors for inappropriate prescriptions.
Br J Clin Pharmacol. 2020 Aug;86(8):1567-1574. doi: 10.1111/bcp.14264. Epub 2020 Mar 13.

本文引用的文献

1
Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials.
Curr Med Res Opin. 2016 Jul;32(7):1277-9. doi: 10.1185/03007995.2016.1170672. Epub 2016 Apr 1.
2
Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.
Chest. 2016 Feb;149(2):315-352. doi: 10.1016/j.chest.2015.11.026. Epub 2016 Jan 7.
3
5
Assessment of dabigatran utilization and prescribing patterns for atrial fibrillation in a physician group practice setting.
Am J Cardiol. 2014 Feb 15;113(4):650-4. doi: 10.1016/j.amjcard.2013.11.008. Epub 2013 Nov 23.
6
Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.
Circulation. 2014 Feb 25;129(8):837-47. doi: 10.1161/CIRCULATIONAHA.113.005119. Epub 2013 Dec 17.
7
New oral therapies for the prevention and treatment of venous thromboembolism.
Am J Health Syst Pharm. 2013 Jan 15;70(2):113-25. doi: 10.2146/ajhp110601.
8
National trends in oral anticoagulant use in the United States, 2007 to 2011.
Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):615-21. doi: 10.1161/CIRCOUTCOMES.112.967299. Epub 2012 Sep 4.
9
Factors influencing doctors' selection of dabigatran in non-valvular atrial fibrillation.
J Eval Clin Pract. 2013 Oct;19(5):938-43. doi: 10.1111/j.1365-2753.2012.01886.x. Epub 2012 Jul 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验